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Abstract 
 
Oxygen is the most important necessity for keeping us all alive. Lungs, in our body 
allows oxygen into our body. Any damage to this vital organ could be fatal. 
Incidences of tracheal and bronchial injuries are at a rise with increase in the number 
of road traffic accidents. Apart from traffic accidents, accidents that involve chest 
crashing, gun wounds, knife penetrations on chest area also damages the respiratory 
tract causing either blunt or penetrating injuries. Most of the injuries due to blunt 
trauma encompasses damage or rupture of trachea and mainstem bronchi. Not only 
injuries, several other conditions like tumors in the airway or congenital 
malformations like severe respiratory stenosis, bronchomalacia and bronchial atresia  
etc. also cause tracheobronchial damages. The theraupeutic approaches for all the 
cases are not well defined and may vary based on the site, extent of lesion and the 
severity of damage. There are problems associated with the traditional surgical 
approches and hence researchers are finding and developing new ways to overcome 
the complications and also to minimize the organ- demand and supply curve. In this 
thesis, we made an attempt to develop smooth muscle layer of the bronchi which is 
the part of the major project lab engineered bronchi which structurally and 
functionally mimics the native bronchi. Herein, we designed and fabricated a 
bioreactor using 3D printing technology and used this construct for development of 
smooth muscle layer of the bronchi model. To support the cells in the construct, we 
decellularized caprine smooth muscle and prepared its hydogel. Mesenchymal stem 
cells were embedded into the pre-gel and was incorporated into the printed 
bioreactor. In this process, we also tried to study the differentiation of MSC into 
smooth muscle cells in the decellularized smooth muscle matrix which stands as 
novelty in this project. 
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Nomenclature 
TBI- Tracheobronchial Injury 
DBE- Disk Bronchial Equivalents 
ALI- Air-Liquid Interface 
ECM- Extra Cellular Matrix 
COPD- Chronic Obstructive Pulmonary Disease 
IF- Immuno Fluorescence 
UCMSC- Umbilical Cord Mesenchymal Stem Cells 
α- MEM- α- Minimum Essential Medium 
PBS- Phosphate Buffered Saline 
SLA- Stereolithography Apparatus 
SDS- Sodium Dodecyl Sulphate 
dSMM- decellularized Smooth Muscle Matrix 
GAG- Glycosamino-Glycans 
BSA- Bovine Serum Albumin 
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Chapter 1 
Introduction 
  
In order to develop new drugs, to understand the complex cellular pathways 
involved in many diseases or to study the basic underlying mechanisms inside a 
human body; two-dimensional culture and animal models are the most prevalent 
models available. However, these models do not completely mimic the in-vivo 
conditions, thus the drugs developed and tested on such models do not pass the 
human trials. Therefore, new concepts or models that can simulate the human in-
vivo conditions are now gaining attention. Cell culture models that are developed in 
the 3D environment has a potential to mimic the microenvironment and 
microarchitecture similar to an in-vivo condition. Moreover, these models can also 
resemble the structural and functional features of the specific tissue or organ that is 
being developed. 
3D printing technology has emerged as a rapid prototyping technique to develop 
models in 3-dimension easily and effectively. The concept of 3D printing was 
initially developed to manufacture complex and personalized machine parts, 
jewellery or to produce replicas of artifacts. This technology was later applied to 
create molds for the development of 3D structure from biocompatible materials. The 
concept of 3D printing when applied to biological research had transformed the 
organ/ tissue engineering methods and popped up as the finest solution in the field of 
medical research[1]. Bioprinting is a promising strategy to develop 3D models 
because of its advantages like high throughput and controlled delivery of scaffold 
and cells, growth factors etc. 3D bioprinting has emerged as a technology that 
ensures the development of in-vivo mimicking structures and is attaining immense 
attention in the recent past[2]. The artificially printed organs not only aid in 
research, training sessions but also solve the organ transplant shortage, which 
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eventually reduces treatment time. Multi-layered skin, heart valves, vascular grafts, 
bone marrow, thyroid glands are few noted structures that are developed using this 
technique[3]. Precise positioning, apt biomaterial, and cell source are the key factors 
for achieving the functional aspects of printed tissue. 
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Chapter 2 
Aim and objective  
   
This project aims at developing an invitro three-dimensional bronchi model that 
mimics the structural and functional features of in-vivo bronchi and also replicates 
the microenvironment found in the lower respiratory tract. The structure of the 
bronchi is achieved when cells are cultured inside a bioreactor which is designed 
and fabricated as part of the project. In order to accomplish this, an attempt is made 
to do the following. 
1. Design and Fabrication of Bioreactor. 
2. Decellularization of caprine smooth muscle  
3. Preparation of smooth muscle gel 
4. Cell culture 
5. Characterization of the developed construct. 
4 
Chapter 3 
Motivation 
   
The Bronchi structure that was aimed to develop in this project serves as a solution 
for the ailments like tracheobronchial injuries, treating conditions like 
tracheobronchial malacia which is predominant in infants, bronchial 
anthracofibrosis- condition generally seen in elderly women. 
3.1 Tracheobronchial Injury 
Tracheobronchial injury is a rare yet serious condition that causes obstruction in 
airway resulting life-threatening respiratory distress. It is a condition that can result 
from high-speed traffic crashes, inhalation of harmful fumes or aspiration of objects 
or liquids[4]. The main stem bronchial injuries comprise the majority of 
tracheobronchial injuries[12]. Although, there might be instant death due to lack of 
oxygen at the time of injury, due to the advancements in the emergency care 
incidences of deaths before reaching hospitals are reduced, thereby increasing the 
diagnosis rate[13].  Rapid diagnosis and treatment are very important in case of TBI 
and any impairment in trachea or bronchus should be fixed as soon as possible, yet 
more often than not , diagnosis and treatment are delayed leading to further 
complications. Complications include pneumonia, bronchiectasis, stenosis, 
formation of scar tissue and infections in the injury site. Treatment options that are 
available to treat TBI are opening the obstructed airway by introducing an 
endotracheal tube, placing a stent or surgically performing end to end anastomosis. 
Although, surgery is not compulsory to treat TBI, surgical reparation is considered 
as the standard treatment in most of the TBI cases[5]. Surgical reparation includes 
end to end anastomosis and closing of flap using sutures. The damaged segment is 
resected and these separated parts are surgically connected using bio absorbable 
sutures in end to end anastomosis[15] (Figure 3.1). However, the maximum length 
of segment that can be resected should not be more that 4 cm[5] else there could be 
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shortening of the tract length and stress on the sutures thus complicating the issues 
further. After the surgery is performed stents are positioned in the surgical place so 
as to keep the airway open. Stents as a treatment option in TBI may loosen over time 
and there are higher chances that these stents relocate to smaller bronchioles and 
block the airway. Also, there are chances of granuloma formation around the stent 
and could lead to inflammation and infections. Not only these, there are several 
more problems when the above treatment options are considered. Few cases were 
reported that introduction of an endotracheal tube, deteriorated TBI instead of 
treating the condition. Multiple forced attempts, inexperience of health 
professionals, multiple repositioning of the cuff, inappropriate positioning of the 
tube are multiple factors that contribute for worsening the condition[14]  
 
   
Figure 3.1: Surgical techniques to treat tracheal injuries [15] 
3.2 Bronchomalacia 
Bronchomalacia is a term for weak cartilage wherein either generalized or localized 
weakness of the bronchial wall collapses and obstructs the lumen (Figure 3.2). It is 
considered to be the congenital defect of the bronchus in the respiratory tract that 
mostly affects infants. In this disease, the main stem bronchi collapses, obstructs air 
passage causing respiratory distress. Because of the weak wall the bronchial lumen 
diameter reduces when patient exhales and increases on inhalation causing distress 
while breathing. This condition of bronchomalacia even worsens if the patient has 
abnormal vascular structure around the respiratory tract. The abnormal blood vessels 
compress the lumen of bronchi as the wall does not possess enough strength to 
maintain the airway open. Congenital defect in larger airways is one the causes of 
irreversible airway obstruction in children[6]. Bronchomalacia is treated by surgical 
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methods either by tracheotomy or inserting prosthesis so that airway remains open. 
Tracheotomy or tracheostomy is a medical procedure which involves insertion of a 
tube by creating an opening in the neck. The tube can be temporarily or permanently 
placed inside the trachea. This tube supports the weak wall of the respiratory tract 
and eases the passage of air. There are complications in this technique either 
immediately after the procedure or over time. The complications that develop over 
time are infections, dried secretions as the mucus is being blocked near the tube, 
rupture of lumen due to rubbing against tube. The next surgical procedure to 
overcome bronchomalacia is to insert stents or prosthesis into the airway. The stents 
are placed in the defective area and are sutured to the native trachea. These sutures 
are placed at the two extremities of the stent to minimize the movement of the stents 
inside the airway. The stents or prosthesis will support the wall till there is re-
epithelialization typically 2-6 months after which they will be removed. As the age 
increases, size of respiratory tract modifies, there are very high chances of prosthesis 
relocation, granuloma formation and stent rejection, failure of the procedure due to 
inappropriate stent length, bacterial growth due to granulation tissue are 
complications that arise with the currently available stents[16]. Secondary 
bronchomalacia that is observed in adults due to recurring polychondritis[7] and 
chest crashing is also treated in the similar approach mentioned above with 
associated complications. 
   
Figure 3.2: Bronchomalacia with current treatment options[16] 
3.3 Bronchial Stenosis 
Bronchial stenosis in adults is a condition that has been associated with several 
ailments in the lung which includes tuberculosis, sarcoidosis, trauma, prolonged 
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endotracheal tube intubation, bronchial sleeve resection, anthrocofibrosis and also 
after lung transplantation. Depending on site and severity of bronchial stenosis, it 
can be managed by various surgical techniques like cryotherapy, LASER therapy, 
surgical resection – re-anastomosis (Figure 3.3) and stent placement. Nevertheless, 
definitive treatment for stenosis is surgical resection and re-anastomosis. However, 
surgical procedures are not possible for patients whose health condition is very poor.  
For those patients, other alternative procedure is placing stents which compresses 
stenosis and opens the airway. Stents implantation often involves complications like 
stent rejection, relocation, granuloma formation. A study revealed that granulation 
tissue formation is the most frequent complication associated with stents. Due to 
several complications with the stents, recently bronchoscopic balloon dilatation 
procedure is being followed in the management of bronchial stenosis[17] (Figure 
3.4). In this technique, under the guidance of bronchoscope a balloon is placed 
across the stenosis. This balloon is steadily inflated with saline solution and is held 
for some time. After deflation of the balloon if the airway is still narrow, the 
procedure is repeated with a balloon of larger diameter. The procedure is considered 
success if there is no narrowing of the airway after 6 months[16]. The potential 
complication of this technique is tearing of the bronchial wall due to excessive 
stretching of the balloon[24]. 
With the advancements in technology, there are treatment options available to treat 
above mentioned disease conditions. But, the treatments are followed with a wide 
number of complications for which the patient has to be treated repeatedly. Hence, 
there is a dire need for a tissue engineered construct that can provide appropriate 
mechanical strength, will not induce any stenosis and keeps the airway open once 
implanted or sutured in the site. Herein, we hypothesize that 3D printing technology 
has a potential to solve the primary disease condition without further complications. 
  
Figure 3.3: Resection of bronchi part and re-anastomosis 
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Figure 3.4: Constricted Bronchi lumen and management using balloon dilatation technique[24] 
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Chapter 4 
Literature Review 
  
4.1 Overview 
The lower respiratory tract also called as a tracheobronchial tree to depict the 
branching assembly of the airway that provides a path for oxygen and carbon-di-
oxide movement. This tract consists of trachea divided into bronchi which further 
divides into bronchioles and to the smallest unit of lungs i.e. alveoli. This complex 
system is partitioned into 23 generations where at each generation the airway 
branches into two smaller airways. The Path from Trachea (0th generation) to 
terminal bronchioles (15th-16th generation) is purely conducting path where no 
gaseous exchange takes place. The later generations further divide into alveolar 
ducts that are completely lined up with alveoli which are gas exchange parts of the 
lung.  
Bronchi is the part that is considered in this project. Similar to the trachea, bronchi 
are also bounded by C-shaped cartilaginous rings. Underneath cartilaginous rings lie 
sub-mucosa which consists of smooth muscle cell layer which controls the diameter 
of the lumen during inspiration and expiration, blood vessels to supply nutrients to 
cells present in sub-mucosa and sub mucosal glands. The innermost lining of the 
lumen is populated with a single layer of Pseudostratified ciliated epithelium and 
goblet cells that produce mucus to protect the mucus lining in the lumen. To connect 
bronchi and other tissues of the lung outer bronchial walls are covered with a band 
of adventitia that acts like a connective tissue. 
In the recent past, researchers have started developing invitro bronchi models to 
study and understand the complex pathways involved in asthma. J.S.Paquaette et, al 
developed a three-dimensional human bronchial models using epithelial and 
fibroblast cells isolated from biopsies. They had produced two different bronchial 
equivalents Disk shaped (DBE) and tubular shaped. Initially, due to fibroblast 
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contractility the bronchial equivalents were not retaining their shape. But then the 
same group had shown that by using peripheral anchorages gel seeded with 
fibroblasts contractility can be reduced. Both these models were developed on such 
peripheral anchorages under four different culture conditions. It was observed that 
serum-free culture media with retinoic acid exposed to ALI culture is the best for 
maintaining bronchial cell properties[8]. A year later the same group used 
asthmatic/non-asthmatic epithelial cells and asthmatic/non-asthmatic fibroblast cells 
and produced asthma bronchial equivalents. A comparative study was done for four 
groups viz. asthma epithelium/asthma fibroblasts, asthma epithelium/non-asthma 
fibroblasts, non-asthma epithelium/ asthma fibroblasts, non-asthma epithelium /non- 
asthma fibroblasts. Results indicated that asthma epithelium cultured on non-asthma 
fibroblasts layers slowly reached confluency but with culture time epithelial layer 
started to detach from mesenchymal layer[9]. In another study Sato et.al proposed 
the use of a prosthesis that is developed for replacing the left main bronchus in 
canine. The main prosthesis is developed using polypropylene mesh which is 
reinforced with c monofilament strings (Figure 4.2). Using freeze-drying technique 
5 mm thickness collagen was deposited on the mesh. This structure was implanted 
into canine whose left main bronchus was blocked due to stenosis. Severe stenosis 
developed in few models that has a lumen diameter of 12 mm. On the contrary, 
models with 15 mm diameter, prosthesis showed no stenosis development. 
Prosthesis coated with 2 % collagen showed complete epithelialization, no mesh 
exposure, and no stenosis. Researchers believe that this prosthesis is a promising 
alternative in the treatment of bronchial stenosis and obstruction[10]. In a recent 
study, Ishikawa et al. developed a 3D epithelial-mesenchymal co-culture model of 
human bronchial tissue to understand the effects of TGF-β1 on airway tissue 
remodelling. The gel containing lung fibroblasts that was applied to a cell culture 
insert and a layer of mucociliary differentiated bronchial epithelial cells were seeded 
on top of gel which enabled direct contact between epithelial and mesenchymal 
cells. ALI culture was also initiated to induce mucociliary differentiation. TGF-β1 
was induced to stimulate airway remodelling in the model. Results showed that 
TGF-β1induced mesenchymal marker vimentin, increase in the number of elongated 
HBEC’s, decrease in E-cadherin suggesting that there is Epithelial-mesenchymal 
11 
transition. Their findings indicate that TGF-β1 effects both epithelial and 
mesenchymal cells and induce gel contraction[11]. Vary recently Elliott et al, 
presented a case of using a decellularized cadaveric trachea, repopulating with cells 
and transplanting it in a patient who was suffering with long segment congenital 
tracheal stenosis. Because of recurrent stenosis the patient described here had 
undergone many surgeries like tracheoplasty, stent insertion, balloon dilatations, 
pericardial patch tracheoplasty, yet none were successful. Considering the condition 
of patient, success with autologous stem cell based tracheal transplant, with the 
consent of HTA, FDA, family, the clinical team proceeded with the procedure. A 
tracheal graft from cadaver was collected and it was decellularized. This 
decellularized trachea was repopulated with autologous cells ex-vivo and were 
cultured in bio-reactor[25]. Once the repopulated trachea was ready for 
implantation, the diseased segment was resected and replaced with the cadaveric 
trachea. The proximal and distal ends of the repopulated decellularized trachea was 
anastomosed with sutures. Immediately post operation, bronchoscopy revealed that 
the graft was intact but after 15 days, the patient developed ventilatory distress. 
Evaluation revealed that there was progressive narrowing of tracheal graft and the 
patient died after 24 h of evaluation. Even though the initial results were 
encouraging, the graft could not support or improve the condition of the patient. The 
reasons for the narrowing of the graft could not be confirmed as they could not 
retrieve the graft after post-mortem.  Hence, there is necessity of improvising the 
techniques so that the failure rate reduces when implanted in the patient (Figure 4.3). 
 
Figure 4.1: Disk bronchial equivalents[8] 
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Figure 4.2:Polypropylene mesh prosthesis[10] 
 
Figure 4.3: Recellularization of Cadaveric trachea with patient derived stem cells[25] 
4.2 Decellularization 
Decellularization is not a new term in tissue engineering and regenerative medicine. 
Decellularization principally means removal of cells from the tissue or organ leaving 
the structural and functional biological material in the organ itself. Most of the 
decellularization protocols involves chemical, physical and enzymatic methods to 
completely remove the cellular content from the tissue. Depending on the tissue 
source methods mentioned above are followed either individually or in combination. 
In the recent past researchers have started exploring decellularization of many 
different tissues and are using them to develop tissue constructs. Recently, Melo et 
al decellularized porcine trachea and used it for the development of bronchial wall. 
Porcine tracheal tissue was decellularized and is placed in a transwell. On the apical 
side epithelial cells were seeded and fibroblast, endothelial cells on the basolateral 
side of the transwell[18] (Figure 4.4). After performing all the necessary 
characterization techniques, the results demonstrated that this decellularized tracheal 
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tissue can be employed for developing bronchial equivalents. They also claim that as 
the co-culture of three different cell lines along with the native membrane mimics 
the in-vivo condition very closely. In another study decellularization of tissue was 
done to understand the role of bronchial epithelium ECM during epithelial cell 
differentiation in COPD patients. In this study Ulf Hedstrom et al obtained lungs 
from COPD stage 4 patients, the bronchial airways were dissected from the lungs 
and were subjected to decellularization (Figure 4.5). These decellularized bronchial 
tissues were repopulated with NHBE and are collected at different time points for 
histology, IHC and other characterization techniques. It was observed that primary 
human bronchial epithelial cells differentiate into airway epithelium on normal and 
COPD bronchial scaffolds[19]. Recent studies reveal that the cadaveric whole 
lungs[21] that are otherwise unsuitable can be decellularized and they might serve as 
source for whole organ engineering which is supposed to have potential to reduce 
the organ demand and supply[20]. 
 
Figure 4.4: Development of bronchial wall in transwell[18] 
 
Figure 4.5: Whole lung decellularization[20] 
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4.3 Summary of the current state of bronchi tissue engineering 
Not long-ago researchers have actively started to develop tissue engineered trachea 
either by using synthetic materials or collagen that is commercially available. After 
that came decellularizing of tissues to develop tissues that closely mimic the native 
environment. There are several studies that had shown decellularization of non-
tracheal tissue to generate tracheal graft. Investigators then started decellularizing 
complete trachea as a whole, re-populate with autologous cells and replace with the 
diseased portion in the patients. As the number of bronchi related cases are 
emerging, researchers have started focusing on bronchi only in the recent past. To 
the best of my knowledge and available literature, a tissue engineered bronchi that 
can structurally and functionally mimic the native bronchi is not yet developed. 
Also, till date, there is no data on models that have bronchial epithelial cells co-
cultured with bronchial smooth muscle cells in the decellularized smooth muscle 
matrix. 
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Chapter 5 
Materials and Methods 
  
5.1 Cell Culture 
Umbilical cord mesenchymal stem cells UCMSC’s that are isolated in our lab are 
used to develop the tissue engineered bronchi. Umbilical cord was collected from a 
nearby hospital and was transported to our lab in the solution containing PBS and 
antibiotics. The collected tissue was washed multiple times with PBS and antibiotic 
solution. Once the cord tissue is devoid of blood, it was then minced into small 
pieces of 2-3 mm and were kept in a sterile T-25 flask. After 14 days of explant 
culture we obtained MSC (Figure 5.1). These cells are used for the project. The cells 
whose passage number is 3 were used for the study. Cells were cultured in DMEM- 
alpha modification media with 10 % fetal bovine serum and 1 % Penicillin-
streptomyocin. Once the cells are confluent in the flasks, they are detached using 
trypsin solution (Trypsin : PBS=1:1) centrifuged at 2000 rpm for 5 min and were 
resuspended in fresh media. 1× 106 /ml of cells were mixed in the pH adjusted pre-
gel and was injected into the temporary part and outermost cylinder of the bioreactor 
assembly (Figure 5.2). 
 
Figure 5.1: Umbilical Cord MSC isolation using explant culture 
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Figure 5.2: Cells + gel in the construct 
5.2 Design of In-house Bio-Reactor 
As discussed previously, to develop a tissue engineered bronchi, static culture 
conditions are being provided. In order to develop a tissue engineered bronchi that 
can structurally and functionally mimic the native bronchi, it is better to provide 
dynamic culture conditions for it to resemble the in-vivo bronchi. Herein, we 
developed a bioreactor model which is structurally similar to bronchi, hypothesizing 
that it would provide proper dynamic conditions to the cells that contribute to the 
development of engineered bronchi. 
5.2.1 CAD design of the bioreactor parts 
The complete bioreactor has 6 different parts, each part having its own importance. 
All the 6 parts when assembled accordingly constitute the bioreactor setup 
mimicking the required microenvironment. The naming convention of the parts is as 
follows and the design specifications of each part are mentioned in the next section. 
For all the parts initially a 2D sketch is developed and its 3D modelling is done in 
AutoCAD v2017. 
5.2.2 Part 1: Innermost cylinder 
This part has a height of 15 mm and a diameter of 6 mm with a thickness of 250 µm. 
Two channels are connected on the either side of this cylinder, one to let in media 
and the other to let the media out. Thereby providing continuous media movement 
throughout. Cells are cultured on the outer surface of this cylinder. The media that is 
flowing inside the cylinder has to reach the cells cultured outside. For this nearly 
160 holes of 600 µm in diameter are created on the curved surface of this cylinder. 
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The importance of this part is to provide nutrients from media to the cells that are on 
the outer surface of this cylinder through diffusion. The diameter of this part is 
chosen in such a way that it obeys the thickness to diameter ration as per the 
literature. The CAD modelled image of the innermost cylinder part is shown in the 
below (Figure 5.3). 
  
Figure 5.3: Innermost cylinder 
5.2.3 Part 2: Temporary cylinder 
The next part after the innermost cylinder is the temporary part that surrounds the 
innermost cylinder. This has a height of 10 mm and diameter of 4 mm with a 
thickness of 250 µm. the main purpose of this part is to support the gel that is being 
filled in between the other parts of the bioreactor. This also has holes of 600 µm to 
diffuse media into the gel. The CAD modelled image of the innermost cylinder part 
is shown in the below (Figure 5.4). 
 
Figure 5.4: Temporary cylinder 
5.2.4 Part 3: Capillaries 
This part has nearly 20 hanging structures named capillaries with each of height 10 
mm and each has a diameter of 1 mm. From literature is was found that nutrients 
from the media cannot diffuse more than 300 µm. The gap between the innermost 
cylinder part and the next part is nearly 2.75 mm and hence the cells in the inner 
layers might not get sufficient nutrients from the media and there are chances of 
necrotic core being formed at the center. To avoid this, we have these capillaries in 
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between the temporary cylinder and the next part, i.e. outermost cylinder (details in 
the next section). The CAD model is shown in (Figure 5.5). 
 
Figure 5.5: Capillaries structure 
5.2.5 Part 4: Outermost cylinder 
The outermost part is last part of the bioreactor assembly. This holds the gel and 
cells in the bioreactor. All the other above-mentioned parts are assembled inside this 
outermost cylinder. It has a height of 10 mm and a diameter of 12.5 mm with a wall 
thickness of 250 µm. Gel with cells will be present in between innermost cylinder 
and this part. This part also has holes of 600 µm throughout its circular surface. 
Equidistant spacing of 400 µm exists between the adjacent holes. The CAD model is 
shown in (Figure 5.6). 
 
Figure 5.6: Outermost cylinder 
5.2.6 Part 5: Outer Jacket 
With a height of 16 mm and diameter of 23 mm this part holds all the above parts 
like a single unit. Inside this part there will be continuous flow of media and through 
diffusion from the small holes present on the circular surface of the outmost cylinder 
nutrients gets absorbed by the gel and cells. It has a conduit connected at the bottom 
to allow media to drain from it. Modelled image is shown below (Figure 5.7). 
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Figure 5.7: Outer-jacket 
5.2.7 Part 6: Cap for outer jacket 
Outer jacket has to be closed on top with a lid like structure for the bioreactor to 
maintain its sterility. This is the part which closes the outer jacket from top. Its 
diameter is same as the outer jacket diameter. A conduit is connected to the top of 
this part to allow media to flow in. Cad model is shown above (Figure 5.7). 
5.3 Bronchi development strategy 
The prepared dSMM gel in which cells are embedded is introduced into the space 
between temporary part and the outermost cylinder In between along with gel, 
capillaries part is also inserted to provide media in all directions. Once the MSCs are 
differentiated into myoblasts, a layer of epithelial cells will be coated towards the 
inner side i.e. lumen side. Then innermost cylinder is inserted into the bioreactor to 
provide epithelial media to epithelial cells. Once both the cell types are fully 
matured we planned to pass air through innermost cylinder and media outside the 
outermost cylinder. This concept of passing air and media at a time in the construct 
provides air liquid interface. Epithelial cells are exposed to air while the smooth 
muscle cells to media and nutrients. We hypothesize that this dynamic ALI culture 
plays a major role to maintain proper functionality of the developed bronchi. 
5.4 Printing of the bioreactor parts 
5.4.1 Modelling Software 
Modelling software, a computer program that is used for developing any three-
dimensional objects, also called 3D modelling. There are many commercial 
modelling softwares available, one of which is AutoCAD by Autodesk. The 
software that we used to develop the bioreactor in our project is AutoCAD. It 
consists of sketch-based features like geometric shapes and operation-based features 
20 
like extrude, fillets etc. There are few mathematical operations like subtract, union, 
intersection etc. The software has drag and drop option which facilitates easy 
modelling.  
3D parts of the bioreactor developed in this project are modelled in this software. 
All parts are individually designed and modelled. Later after printing all the parts 
were assembled 
5.4.2 Printing technology 
Stereolithography is the 3D printing technology that is used to print the parts of the 
bioreactor. Stereolithography, a layer-by-layer printing technology that uses 
stereolithography apparatus (SLA) (Figure 5.9) to convert liquid parts to solid 
objects. The main components in the machine includes LASER source, 
photosensitive resin, XY scanning mirror, lenses, elevator, vat to hold the resin, 
wiper to maintain uniform surface of resin while printing (Figure 5.8). 
 
Figure 5.8: Parts of SLA (Source: Formlabs webpage) 
 
Figure 5.9: SLA desktop 3D printer by Formlabs 
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5.4.2.1. Principle of Operation 
The model that has to be printed is sent to the printer. A vat holds the photo-
sensitive resin; a thin layer of photopolymer is exposed to the light source. As per 
the model, the LASER light hits the polymer. The photo-sensitive liquid hardens 
when the LASER light touches it, forming the first layer of the 3D object. Once this 
first layer is printed, the elevator rises in Z-direction exposing a new layer of 
uncured resin to print the next layer. This process is repeated until the printing of 
entire object is done. Once the print is done, post processing of the object removes 
any uncured resin from the print (Figure 5.10). 
 
Figure 5.10: SLA operation principle (Source: gcreate- gmax 3D printer forum) 
5.4.3 Printing software 
Printing software is necessary to convert the files from one format to the format 
which a machine understands. The output format from the modelling software is 
quite different from the machine language. In our project, parts that are modelled in 
AutoCAD has an extension “.dwg”. These CAD files has to be converted into 
printing software understandable language. Standard Tessellation Language (.stl) is 
one such type of language that is commonly used for stereolithography and other 
additive manufacturing processes. “.stl” is the format that is understood by the 
printing software Preform. The software preform is provided by Formlabs which 
takes .stl as input and gives output as .preform job file which is proprietary format of 
Formlabs. From the software itself when we give the print command, the file is 
exported to the printer for printing.  
5.5 Decellularization of smooth muscle 
Caprine smooth muscle was collected from a nearby slaughter house and was used 
for the research with the approval from the trader. The decellularization of smooth 
muscle was performed following the protocol that was published for decellularizing 
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skeletal muscle with modifications[22]. Briefly, the tissue was washed in distilled 
water to remove any biological wastes and chopped into small pieces of around 2-3 
mm. These chopped pieces were stirred in 1 % SDS in distilled water for 24 h. This 
is followed by treating the chopped pieces with 1 % Triton X-100 for 24 h. Then 
they are thoroughly washed in distilled water to remove any left-over detergents. 
After washing the decellularized tissue is lyophilized and stored at -20 0C for further 
use (Figure 5.11). 
 
Figure 5.11: Decellularization process 
5.6 Preparation of decellularized smooth muscle matrix hydrogel 
Lyophilized decellularized Smooth Muscle Matrix (dSMM) is crushed in the 
presence of liquid nitrogen. Required amount of crushed tissue is weighed and 
digested in 0.01 M HCl in the presence of pepsin (10% of the total weight of tissue) 
for 24 h.[22] After complete solubilization, pH was checked and was in the range of 
2-2.5. pH was then adjusted to nearly 7.4 by adding 10 M NaOH solution in cold 
condition preferably less than 4 0C. After adjusting pH the pre-gel was stored at 4 0C 
until further use. 
5.7 Characterization of prepared dSMM gel 
5.7.1 GAG estimation 
To analyze the amount of GAG present in the native tissue and decellularized tissue 
GAG estimation was done. This analysis will help us understand the extent of ECM 
components that are being preserved during decellularization. The native and 
decellularized tissue were digested in papain solution for 16 h at 60 0C. the GAG 
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content was estimated using 1,9-dimethylmethylene blue solution. The absorbance 
was measured at a wavelength of 492 nm. For comparison, a standard curve was 
generated in advance using chondroitin sulphate solution 
5.7.2 DNA estimation 
To quantify the amount of DNA present in the native tissue and decellularized 
tissue, we performed DNA estimation using Biodrop instrument.  For this 
estimation, the native muscle and decellularized muscle were digested in papain 
solution at 60 0C for 16 h. after initial calibration of the instrument, 1 µl of digested 
native muscle solution was loaded to the orifice and the DNA content was noted. 
Then, 1 µl of water was added to clean up the orifice, so that there is are no previous 
sample particles. Then 1 µl of digested decellularized muscle solution was added to 
the orifice and the DNA content was noted. 
5.7.3 Collagen estimation 
To quantitatively measure that collagen content present in the decellularized tissue 
and the native tissue, hydroxyproline assay is performed. In this assay, both native 
and decellularized tissue samples are digested in 0.5 % collagenase A solution and 
were incubated at 37 0C overnight. Then freshly prepared assay buffer and 
chloramine-T is added to the sample. After 15 min at RT, DMBA solution is added 
and kept at 60 0C for 20 min. Later absorbance reading was taken at 570 nm. The 
standard that was used for comparison is hydroxyproline.   
5.7.4 Rheology 
The mechanical properties like viscosity and modulus of the pre-gel that was 
prepared was measured using rheometer. The decellularized Smooth muscle matrix 
was digested in pepsin and the pre-gel was used for measurements. Sample was run 
on a parallel plate rheometer (Anton Par MCR301, Software: Rheoplus V3). The 
three measurements that were done on the sample are viscosity, stress and storage- 
loss modulus. For viscosity measurement, sample was loaded onto the fixed parallel 
plate and the strain rate was varied from 10 s-1 to 1000 s-1 and the graph viscosity vs. 
strain rate was plotted. In the same measurement we could also plot a graph between 
Shear stress and strain rate. Amplitude sweep is another graph that was plotted. In 
the measurement, angular frequency is kept constant at 10 rad/s and strain is 
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increased from 1 % to 100 % with a slope of 5 pt./Dec. In the amplitude sweep test, 
we get the values of storage and loss modulus with respect to change in strain 
percentage. The temperature at which the tests were performed was 25 0C. 
5.8 Cells viability and gene expression 
5.8.1 Live dead assay 
Live dead assay was performed to check the viability of cells when embedded in the 
dSMM gel. UCMSC cells were embedded into the gel and was kept in the incubator 
for 45 min. After gelation media was added and was kept in incubator at 37 0C for 
48 h. Post 48 h, media was removed and gels were washed with PBS to completely 
remove the media. Calcein, ethidium homodimer was mixed in the ratio of 1:4 in 1 
ml of PBS. The washed samples were then immersed in the assay solution prepared 
and was incubated for 45 min. After 45 min, the samples were taken on a glass slide 
and was observed under fluorescence microscope at the excitation/emission 
wavelength of 494/517 nm for calcein and 528/614 nm for ethidium homodimer 
respectively. 
5.8.2 Immunofluorescence 
Immunofluorescence is a technique that is used to locate the distribution of 
biomolecules in the sample primarily making use of fluorophores to visualize the 
location of antibodies. In this project, Umbilical cord Mesenchymal stem cells are 
embedded in the decellularized smooth muscle gel. We hypothesize that these 
UCMSC will differentiate into Smooth muscle cell due to the presence of similar 
cues in their surroundings. In order to check the differentiation of MSC to SMC we 
used alpha smooth muscle actin (an early stage marker for SMC differentiation) 
primary antibody and Alexa fluor 647 anti-mouse as secondary antibody. We used 
Hoechst stain for staining the nucleus. The samples under study were initially fixed 
in 10 % formalin and are washed multiple times with PBS. Then, they are washed 
with 0.1 % triton which breaks the cell membrane. Samples were then added to 1 % 
BSA solution which acts as blocking buffer that blocks the unwanted sites in the 
sample for 30 min at 37 0C. After BSA, primary antibody is added and is kept in 4 
0C for overnight. Next day, after thorough washing with PBS, secondary antibody 
i.e. Alexa fluor 647 (Bright red fluorescence dye) that binds to primary antibody is 
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added and was incubated at 37 0C for 2 h. Later Hoechst stain was added and was 
taken for confocal imaging. The excitation/ emission wavelengths that are used for 
secondary antibody and Hoechst stain are in the range of 650/665 nm and 355/465 
nm respectively. 
26 
Chapter 6 
Results and Discussion 
  
6.1 Development of In-house bioreactor 
In order to develop a three-dimensional lab engineered bronchi that mimics the 
structural and functional aspects as the native bronchi, the main part was 
development of the bioreactor which resembles the native tissue. So, to mimic this 
the first thing was to create a cylindrical structure, then to support the main structure 
and to make sure that media perfuses into all the directions and into all the layers we 
designed all the above-mentioned parts. Holes were also created on the cylindrical 
surface of the cylinder so that media enters into the construct with ease. After the 
shape, the next thing was the size of the construct. From literature, the thickness to 
diameter ratio should be in between 0.2 to 0.3. So, as per this we decided upon our 
diameter and thickness and the T/D ratio of our construct is 0.23 which is well 
within the range. Once all the parameters are decided, we started modelling in 
AutoCAD. The modelled constructs were exported to preform printing software and 
was printed using Formlabs 3D SLA printer. After printing, the printing accuracy 
i.e. measurement of the holes was measured using Zeta 3D optical Profiler.  The 
average size of holes that were measured was found out to be 510 µm while the 
designed diameter was 600 µm (Figure 6.1). There is a decrease of almost 15 % in 
diameter after printing. As the size decreases the accuracy also goes down because 
as the area to solidify is less nearby layers are also exposed to light and might get 
polymerize to some extent. This could be the reason for decrease in print dimensions 
when compared to design. 
27 
 
Figure 6.1: Hole measurement using 3D optical profiler 
6.2 Preparation and Characterization of decellularized smooth muscle 
matrix (dSMM) 
The main aim of decellularization is to remove the maximum cellular content while 
retaining the majority of ECM components. We had made an attempt to 
decellularize the native smooth muscle tissue using chemical detergents like SDS 
and Triton X-100. SDS is a detergent that disrupts the cell membrane. Triton X-100 
disrupts the hydrogen bonding in the lipid bilayer and enters the interiors of the cell 
releasing the cellular contents into the matrix. To analyze the extent of protein 
retention in the decellularized matrix we performed GAG and Collagen estimation 
with DMMB assay and Hydroxyproline assay respectively. The GAG content in the 
decellularized matrix was found out to be 9 % more than the native tissue (Figure 
6.2). Also, the collagen content in the decellularized smooth muscle matrix was 
almost 200 % more when compared to the native smooth muscle tissue (Figure 6.2). 
When we decellularize a tissue, the cellular contents get washed off compressing the 
matrix. So, if we take same amount of native and decellularized tissue it is 
hypothesized that the protein content in decellularized is more as there are no cells 
and protein content is less in native tissue as there are cells along with the matrix. 
This probably could be the reason for increase in GAG and collagen content in 
decellularized ECM. We could observe only slight decrease of about 13 % in the 
DNA content in decellularized tissue when compared to native tissue (Figure 6.3). 
The probable reason could be due to insufficient decellularization. When we 
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compare DNA content with ECM components retention in the decellularized tissue, 
it can be also concluded that due to inadequate decellularization we could observe 
more ECM retention.  
 
Figure 6.2: GAG, Collagen Content in % 
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Figure 6.3: DNA Content expressed as percentage 
6.3 Rheological Characterization of dSMM hydrogel 
The percentage of gel to be prepared was decided based on viscosity. We want our 
gel to provide support for the cells we embed in the gel and hence 5 % gel was 
prepared which had high viscosity when compared to 1 % and 3 % gels. The 
digested dSMM was acidic in nature and was adjusted to neutral pH by adding 10 M 
NaOH. After adjusting pH, when allowed to incubate at a temperature 37 0C it 
formed a stable gel. The 5 % gel (pH ~1) was subjected to rheology tests to evaluate 
its behavior when it is subjected to a shear rate in the range if 10 – 1000 s-1 at 25 0C. 
The gel showed a shear thinning behavior which is the behavior of gels that is 
required for printing (Figure 6.4). Amplitude sweep test was performed to measure 
the dependence of loss and storage moduli with change in strain %, in which 
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frequency was constant at 10 rad/s, while strain % increased from 1 % - 100 %.  At 
strain % between 10 % - 100 % the elastic property was more when compared to 
viscous property indicating the hydrogel’s ability to store deformation energy in 
elastic manner (Figure 6.4). So higher the storage modulus the hydrogel can retain 
its shape in this strain conditions. Higher G’ implies higher strength and mechanical 
rigidity. 
   
Figure 6.4: Graphs indicating shear thinning property and higher G' implying high rigidity and 
mechanical strength 
6.4 Cell Viability 
Cells were embedded in two different percentages of gels, 3 % and 5 %. Both these 
gels were considered for checking the viability of cells. It was observed that the cells 
that are embedded in 3 % gel were almost dead, no viable cells observed (Figure 
6.5). While 80 % viability could be observed in 5 % gel on Day 3 of culture (Figure 
6.6). Stiffness of the gel could be factor that is affecting the viability of cells in the 
two different percentage gels. 
 
Figure 6.5: Ethidium homodimer staining dead cells in 3 % gel 
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Figure 6.6: Green Fluorescence by Calcein Stain indicating live cells in 5 % gel 
6.5 Immunofluorescence 
After culturing UCMSC in the gel for about 7 days, we fixed the sample and stained 
it with alpha SMA, an early marker for SMC differentiation, Hoechst stain to stain 
nucleus and observed under confocal microscope. We could observe nucleus stained 
blue in colour and the secondary antibody showed florescence surrounding the 
nucleus (Figure 6.7). This implies the potential of decellularized smooth muscle 
matrix to support UCMSC to differentiate into SMC in the dSMM gel. This 
indicates the importance of ECM microenvironment for directing the cells to 
specific lineage. 
 
Figure 6.7: Nucleus stained with Hoechst blue fluorescent dye; alpha SMA stained red; merged 
picture indicating actin filaments surrounding nucleus 
31 
Chapter 7 
Conclusion and Future Scope 
In conclusion this study shows the feasibility of using the fabricated bioreactor for 
bronchi tissue engineering. This study revealed that decellularized smooth muscle 
hydrogel can be a potential candidate for the reconstruction of bronchial muscle as 
evidenced from the differentiation of UCMSC to SMA expressing cells, though it is 
a preliminary data. We also supported by the practicality of preparing decellularized 
smooth muscle hydrogel successfully as evidenced from the high GAG and 
Collagen content, though the DNA content demands modification in the 
decellularization protocol. Rheological behavior of the gel revealed the suitability of 
the prepared gel for 3D bioprinting applications.  
As part of future scope, we would like to include epithelial cells layer once the 
smooth muscle layer is developed. This will be followed by ALI culture in dynamic 
conditions and further validating the construct. These outcomes in this preliminary 
study encourages us to take the project forward in development of complete 3D in 
vitro bronchi, which has a potential to overcome the complications that are 
encountered during standard treatment procedures.  
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